Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Julphar
Fish and Richardson
Accenture
Farmers Insurance
Cipla
Daiichi Sankyo
Cerilliant

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 076164

« Back to Dashboard

NDA 076164 describes LISINOPRIL, which is a drug marketed by Accord Hlthcare, Apotex Inc, Aurobindo, Casi Pharms Inc, Hikma Intl Pharms, Invagen Pharms, Ivax Sub Teva Pharms, Lupin, Mylan, Prinston Inc, Sandoz, Sun Pharm Inds Ltd, Teva, Watson Labs, and Wockhardt, and is included in thirty-one NDAs. It is available from seventy-eight suppliers. Additional details are available on the LISINOPRIL profile page.

The generic ingredient in LISINOPRIL is hydrochlorothiazide; lisinopril. There are thirty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; lisinopril profile page.
Summary for 076164
Tradename:LISINOPRIL
Applicant:Prinston Inc
Ingredient:lisinopril
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 076164
Medical Subject Heading (MeSH) Categories for 076164
Suppliers and Packaging for NDA: 076164
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LISINOPRIL lisinopril TABLET;ORAL 076164 ANDA NCS HealthCare of KY, Inc dba Vangard Labs 0615-8064 N 0615-8064-05
LISINOPRIL lisinopril TABLET;ORAL 076164 ANDA NCS HealthCare of KY, Inc dba Vangard Labs 0615-8064 N 0615-8064-30

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:Jul 1, 2002TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength30MG
Approval Date:Jul 1, 2002TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength40MG
Approval Date:Jul 1, 2002TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Chubb
Deloitte
QuintilesIMS
Daiichi Sankyo
Harvard Business School
Johnson and Johnson
Cerilliant
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.